// App-Quantinova.ai

TCT-457 : Paclitaxel - eluting stents vs Everolimus - eluting Coronary Stents in a Diabetic population: 2 Years Follow-up of TUXEDO-India Trial

Researchers

Presenter

  • Upendra Kaul

Principal Investigators

  • Rajpal K. Abhaichand

  • Tejas Patel

  • Darshan Banker

  • Atul Abhyankar

  • Ajit Mullasari

  • Sanjay Shah

  • Rajneesh Jain

  • premchand rajendra kumar

  • C.G. Bahuleyan

Medical Centers

  • Bankers Heart Institute, Vadodara, Gujarat, India

  • GKNM Hospital, Coimbatore, India

  • APEX Heart Institute, Ahmedabad, Gujarat, India

  • Gangaram Hospital, Delhi, India

  • NIMS, Hyderabad, Hyderabad, India

  • New York University School of Medicine, New York, New York, United States

  • The Madras Medical Mission, Chennai, India

  • Fortis Escorts Hospital, New Delhi, India

  • Sahajanand Medical, Surat, Gujarat, India

  • Ananthapuri Hospitals and Research Institute, Trivandrum, Kerala, India

  • Apex Heart Institute, Ahmedabad, India

Locations

  • United States

  • India

Companies

  • Fortis Healthcare Li

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Myocardial infarction

  • Venous thrombosis

  • Coronary Artery Disease

Biomarkers

  • N/A

Drug/Treatment

  • Everolimus

  • Paclitaxel

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved